Understand the source comparison
Peptides for High Cholesterol Protocol Evidence Guide: Comparison
| Peptide | Proposed Mechanism | Strongest Published Evidence | LDL-C Reduction (Mean %) | Triglyceride Reduction (Mean %) | Adjunctive Use Case | Bottom Line ||—|—|—|—|—|—|| Thymosin Alpha-1 | T-cell immune modulation, reduced ox-LDL | Phase 2 RCT (Chengdu Un
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Proposed Mechanism | Strongest Published Evidence | LDL-C Reduction (Mean %) | Triglyceride Reduction (Mean %) | Adjunctive Use Case | Bottom Line ||—|—|—|—|—|—|| Thymosin Alpha-1 | T-cell immune modulation, reduced ox-LDL | Phase 2 RCT (Chengdu University, 2021) | −3.2% (not significant) | −15.4% | Patients with elevated hs-CRP despite statin therapy | Strongest human data for inflammatory lipid markers || BPC-157 | eNOS upregulation, improved endothelial function | Preclinical only (ApoE−/− mice, Zagreb) | No human data | No human data | Vascular repair in post-MI or stent patients (theoretical) | No published human lipid outcomes || AOD-9604 | Beta-3 adrenergic lipolysis, visceral fat reduction | Phase 2 obesity trial (2015) | 0% (no change) | −12.7% | Metabolic syndrome with hypertriglyceridemia | Effective for triglycerides, not LDL-C || Thymalin | Thymic peptide, immune regulation | Case series (Russian literature, limited English translation) | No controlled data | N